Webcasts

How much do you have to reduce Lp(a) to achieve significant clinical benefit?

Bempedoic acid: The new kid on the block

Immunotherapies in homozygous FH: Alirocumab and evinacumab

Remnant lipoproteins and impact of PCSK9 inhibition

Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES

Genetic risk scores: How much do they add?

Inclisiran: Update on efficacy, dosing regimen, safety and COVT trial

Lp(a): Findings in ODYSSEY OUTCOMES

What’s new in very high-risk patients?

Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes

Lp(a): Risk factor or causal factor? A critical appraisal

ODYSSEY OUTCOMES and stroke events

Treat ischaemic stroke to target

Endothelial LDL transcytosis in atherosclerosis

Emerging lipid science: ApoE and chronic disease

ODYSSEY OUTCOMES: Update

New data from FOURIER and design of the VESALIUS-CV Trial

PCSK9 Genetics: New Insights


Jan Boren
Hepatic lipid metabolism: Storage vs secretion


Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins